Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.

ABSTRACT:

Background

The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. The vaccine will soon be deployed at scale in sub-Saharan Africa. This study aimed to understand the caregiver and community acceptability of the R21/Matrix-M vaccine alongside existing malaria prevention interventions, according to the communities of participants in the seasonal R21/Matrix-M phase III trial in Mali.

Methods

Qualitative data were collected to assess the acceptability of the R21/Matrix-M vaccine alongside the three R21/Matrix-M or control vaccine priming injections given in the first year of the trial. A total of 33 in-depth interviews (IDIs), 12 focus group discussions (FGDs) and 45 exit

SUBMITTER: Diawara H 

PROVIDER: S-EPMC11795384 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature